Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.80 |
| ▸ | EGFR | P00533 | 15/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.55 |
| ▸ | TEC | P42680 | 3/20 | 0.55 |
| ▸ | TXK | P42681 | 3/20 | 0.55 |
| ▸ | BLK | P51451 | 3/20 | 0.55 |
| ▸ | BMX | P51813 | 3/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.55 |
| ▸ | JAK3 | P52333 | 2/20 | 0.55 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17675594 | 0.92 | BTK (0.80) | BTKEGFRERBB2TECTXK | |
| SCHEMBL17675595 | 0.90 | BTK (0.82) | BTKEGFRERBB2TECTXK | |
| SCHEMBL17675328 | 0.90 | BTK (0.81) | BTKEGFRERBB2TECTXK | |
| SCHEMBL17675357 | 0.89 | BTK (0.78) | BTKEGFRERBB2TECTXK | |
| SCHEMBL17675249 | 0.89 | BTK (0.80) | BTKEGFRERBB2TECTXK | |
| SCHEMBL17675218 | 0.89 | BTK (1.00) | BTKEGFRERBB2TECTXK | |
| SCHEMBL17675250 | 0.88 | BTK (0.78) | BTKEGFRERBB2TECTXK | |
| SCHEMBL17675262 | 0.86 | BTK (0.83) | BTKEGFRERBB2TECTXK | |
| SCHEMBL17675193 | 0.84 | BTK (0.74) | BTKEGFRERBB2TECTXK | |
| SCHEMBL17675520 | 0.83 | BTK (0.73) | BTKEGFRERBB2TECTXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016055982-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS | ACERTA PHARMA B.V. (NL) | 2016-04-14 | — | — | WO | claimed |